BARDA contract commits initial USD16.9m to support Avita’s FDA approval trial for treatment of thermal burn injuries and procure 5000-plus ReCell® devices.
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced receipt of US$3.2 million in cash under the Australian Federal Government’s Research and Development (R&D) Tax Incentive program. This program provides a 45 percent refundable tax offset for qualifying R&D in Australia, where Nexvet conducts its drug discovery activities, including PETization™.
Read more about Nexvet Receives FY2015 Cash Refund of $3.2 Million
SeaDragon raises $10.009 million via rights offer and shortfall bookbuild, and additional placement.
Read more about SeaDragon raises $10.009 million
Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, notes two recent legal settlements — awarding funding for the purchase of a REX robot and funding for Robot-Assisted Physiotherapy with REX.
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced it has secured a dedicated biologics manufacturing facility in Tullamore, Ireland. The transaction is supported by the Irish Government’s Department of Jobs, Enterprise & Innovation through IDA Ireland, their foreign investment agency.